CVie Therapeutics Limited

CVie Therapeutics Limited (CVie) is a Taiwan-based joint venture founded in 2013 by Lee’s Pharmaceutical Holdings Limited and renowned venture capitals from the U.S. and Taiwan. It is a stand-alone drug development company specialized in cardiovascular diseases. CVie currently owns two phase IIb assets that target cardiovascular diseases with significant unmet medical needs. Rostafuroxin is a novel precision medicine targeting hypertensive patients with specified genetic profiles with better efficacy and safety than conventional therapies. Istaroxime is a first-in-class luso-inotropic medicine for the treatment of acute heart failure and will have fewer adverse effects than conventional inotropes, namely, increased heart rate, arrhythmia, increased oxygen consumption and hypotension.